Pascal Jezequel
Overview
Explore the profile of Pascal Jezequel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sablin M, Gestraud P, Jonas S, Lamy C, Lacroix-Triki M, Bachelot T, et al.
Br J Cancer
. 2024 Aug;
131(6):1060-1067.
PMID: 39090361
Background: Copy number alterations (CNA) are acquired during the evolution of cancers from their early stage to metastatic stage. This study aims at analysing the clinical value of the identified...
2.
Clavreul A, Guette C, Lasla H, Rousseau A, Blanchet O, Henry C, et al.
Mol Oncol
. 2024 May;
18(11):2783-2800.
PMID: 38803161
Proteomics has been little used for the identification of novel prognostic and/or therapeutic markers in isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GB). In this study, we analyzed 50 tumor and 30 serum...
3.
Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype
Jezequel P, Lasla H, Gouraud W, Basseville A, Michel B, Frenel J, et al.
Breast Cancer
. 2024 May;
31(5):825-840.
PMID: 38777987
Background: Robust molecular subtyping of triple-negative breast cancer (TNBC) is a prerequisite for the success of precision medicine. Today, there is a clear consensus on three TNBC molecular subtypes: luminal...
4.
Basseville A, Cordier C, Ben Azzouz F, Gouraud W, Lasla H, Panloup F, et al.
Cancer Res Commun
. 2023 Mar;
2(8):857-869.
PMID: 36923306
Significance: The development of personalized and precision medicine is the future of cancer therapy. With only two gene expression signatures approved by FDA for breast cancer, we are in need...
5.
Moreau N, Rousseau C, Fourcade C, Santini G, Ferrer L, Lacombe M, et al.
Annu Int Conf IEEE Eng Med Biol Soc
. 2022 Sep;
2022:4736-4739.
PMID: 36086627
In metastatic breast cancer, bone metastases are prevalent and associated with multiple complications. Assessing their response to treatment is therefore crucial. Most deep learning methods segment or detect lesions on...
6.
Fourcade C, Ferrer L, Moreau N, Santini G, Brennan A, Rousseau C, et al.
Phys Med Biol
. 2022 Jul;
67(15).
PMID: 35785776
This paper proposes a novel approach for the longitudinal registration of PET imaging acquired for the monitoring of patients with metastatic breast cancer. Unlike with other image analysis tasks, the...
7.
Domergue C, Martin E, Lemarie C, Jezequel P, Frenel J, Augereau P, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626113
Purpose: Investigates the link between HER2 status and histological response after neoadjuvant chemotherapy in patients with early TNBC. Methods: We retrieved clinical and anatomopathological data retrospectively from 449 patients treated...
8.
Bouron C, Mathie C, Seegers V, Morel O, Jezequel P, Lasla H, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158904
(1) Background: triple-negative breast cancer (TNBC) remains a clinical and therapeutic challenge primarily affecting young women with poor prognosis. TNBC is currently treated as a single entity but presents a...
9.
Moreau N, Rousseau C, Fourcade C, Santini G, Brennan A, Ferrer L, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008265
Metastatic breast cancer patients receive lifelong medication and are regularly monitored for disease progression. The aim of this work was to (1) propose networks to segment breast cancer metastatic lesions...
10.
Patsouris A, Diop K, Tredan O, Nenciu D, Goncalves A, Arnedos M, et al.
Eur J Cancer
. 2021 Nov;
159:283-295.
PMID: 34837859
Background: Breast cancer may present genomic alterations leading to homologous recombination deficiency (HRD). PARP inhibitors have proven their efficacy in patients with HER2-negative (HER2-) metastatic breast cancer (mBC) harbouring germline...